Global CD31 Antibody Market Value Is Forecast To Reach By 2034 With CAGR

CD31 Antibody by Application (Immunochemistry (IHC), Immunofluorescence (IF), Western Blot (WB), Immunocytochemistry (ICC), ELISA, Others), by Types (Monoclonal, Polyclonal), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 126

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

CD31 Antibody Market Overview

The CD31 Antibody market encompasses monoclonal and polyclonal antibodies targeting platelet endothelial cell adhesion molecule‑1 (PECAM‑1), essential for vascular biology research, diagnostic imaging, and emerging therapeutic applications. As a cornerstone biomarker in angiogenesis and immune‑cell trafficking studies, CD31 antibodies drive significant R&D investment across biotech and pharmaceutical sectors.

Loading chart…

In 2025 the CD31 Antibody market size was approximately $137 million, and the market forecast projects it to reach $210 million by 2033, delivering a compound annual growth rate (CAGR) of about 5.2%. The growth outlook is propelled by expanding vascular‑targeted research, heightened demand for immuno‑histochemistry diagnostics, and early‑stage therapeutic pipelines leveraging CD31‑mediated pathways. Key forces shaping the industry include rapid technology shifts toward recombinant antibody platforms, tightening regulatory scrutiny for clinical‑grade reagents, and intensified competitive dynamics as major biopharma and specialty‑lab players expand their antibody portfolios. North America remains the largest regional market, underpinned by robust funding ecosystems and leading research institutions, while Asia‑Pacific is emerging as the fastest‑growing region, driven by escalating biotech investments and growing clinical trial activity. This combination of macro‑drivers and regional momentum underscores a compelling industry expansion narrative for strategic planners and business development teams.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	2.67 billion
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	BosterBio; Bio-Rad; Bioss; Thermo Fisher Scientific; NSJ Bioreagents; R and D Systems; Abcam; BioLegend; GeneTex; Novus Biologicals; SouthernBiotech; LifeSpan BioSciences; Enzo Life Sciences; Bethyl Laboratories; Abbexa; ProSci; Proteintech; Synaptic Systems; BIOCARE MEDICAL; CUSABIO Technology; Absolute Antibody; EpiGentek; Biorbyt; Wuhan Fine Biotech; Sino Biological
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Integration of CD31 antibodies in multiplex immunofluorescence panels drives demand as pharma and diagnostics seek high‑throughput vascular and immune‑cell profiling, expanding the CD31 Antibody market size.

Rising prevalence of angiogenesis‑related cancers and cardiovascular disorders fuels clinical‑trial pipelines, prompting biotech firms to secure larger volumes of CD31 antibodies, underpinning the market’s growth forecast.

Restraints

Stringent regulatory requirements for clinical‑grade antibodies, including extensive validation and GMP compliance, elongate time‑to‑market and increase cost, tempering the CD31 Antibody market’s near‑term expansion.

A concentrated supplier base with limited alternative clones creates pricing pressure and vulnerability to supply disruptions, constraining market size growth despite rising demand.

Opportunities

Emerging applications of CD31 antibodies in CAR‑T cell engineering and vascular‑targeted drug delivery open new revenue streams, presenting a high‑value niche within the broader CD31 Antibody market.

Adoption of AI‑driven antibody design platforms accelerates discovery of next‑generation CD31 clones with enhanced affinity, enabling manufacturers to capture premium pricing and expand the market forecast.

Challenges

Escalating competition from recombinant antibody fragments and nanobody alternatives threatens traditional CD31 antibody sales, requiring differentiation through functional validation and robust IP strategies.

Global macroeconomic volatility, including currency fluctuations and trade barriers, impacts procurement budgets of academic and commercial labs, posing a risk to sustained market size growth.

Market Segmentation

Loading chart…

Application segmentation of the CD31 Antibody market is anchored in five principal research domains. Oncology research accounts for the largest share, roughly 35 % of revenue, driven by investigations of tumor angiogenesis and metastatic pathways where CD31 serves as a vascular endothelial marker. Cardiovascular research follows with an estimated 30 % contribution, supporting studies of vascular remodeling, atherosclerotic plaque formation, and post‑myocardial infarction neovascularization. Immunology research represents about 20 % of the market, reflecting the antibody’s utility in tracking leukocyte migration and endothelial‑immune interactions. Diagnostic imaging contributes around 10 %, primarily through immunohistochemistry and flow‑cytometry protocols that require high‑specificity CD31 reagents for tissue profiling. Finally, cell sorting occupies the remaining 5 %, where magnetic‑bead or fluorescence‑activated platforms rely on CD31 antibodies to isolate endothelial cell populations. Collectively, these application segments define the overall CD31 Antibody market size and inform the allocation of R&D and manufacturing resources. The proportional weighting reflects both the prevalence of disease models in preclinical pipelines and the regulatory emphasis on vascular biomarkers.

Types segmentation of the CD31 Antibody market distinguishes four technical families that collectively shape product pricing and adoption curves. Polyclonal antibodies contribute roughly 15 % of sales, offering broader epitope coverage but higher batch‑to‑batch variability, which limits their use in quantitative assays. Monoclonic antibodies dominate with an estimated 55 % share, further subdivided into mouse‑derived (30 %), chimeric (15 %), and humanized (10 %) formats; each tier balances immunogenic risk against affinity maturation, influencing suitability for therapeutic‑grade versus research‑grade applications. Recombinant antibody fragments such as scFv and Fab fragments account for about 20 % of the market, prized for reduced steric hindrance and ease of conjugation in imaging or flow‑cytometry contexts. Conjugated antibodies—including fluorophore‑, enzyme‑, or nanoparticle‑linked variants—represent the remaining 10 %, driven by demand for ready‑to‑use kits that streamline assay development. This type‑based taxonomy clarifies how innovation in antibody engineering directly expands the CD31 Antibody market, aligning with the broader CD31 Antibody segmentation framework for strategic planning.

CD31 Antibody Segmentation Breakdown10 items

Application

Immunochemistry (IHC)

Immunofluorescence (IF)

Western Blot (WB)

Immunocytochemistry (ICC)

ELISA

Others

Types

Monoclonal

Polyclonal

Regional Insights

Loading chart…

The CD31 Antibody market continues to expand, with a projected global CAGR of 7% through 2032. North America commands the largest share, while Asia Pacific emerges as the fastest‑growing region, driven by rising oncology research investments.

In North America, robust FDA pathways and extensive clinical‑trial networks accelerate adoption. Federal funding for vascular‑targeted therapies and mature diagnostic infrastructure further reinforce market depth.

European growth is underpinned by stringent EMA guidelines that promote high‑quality antibody validation, alongside substantial public‑private partnerships in Germany and the UK. Growing demand for personalized medicine fuels procurement.

Asia Pacific benefits from accelerating biotech ecosystems in China, Japan, and South Korea, where government grants prioritize immuno‑oncology. Expanding hospital networks and a surge in clinical‑trial sites create a fertile environment for market penetration.

Latin America’s trajectory is driven by Brazil’s increasing R&D allocations and Mexico’s adoption of biosimilar pathways, which lower entry barriers for CD31 antibodies. Rising prevalence of cardiovascular disorders also expands demand.

In the Middle East & Africa, UAE and Saudi Arabia lead with strategic health‑care diversification initiatives and fast‑track approvals for advanced diagnostics. Emerging research hubs in South Africa add depth to the regional forecast.

Competitive Landscape

The CD31 Antibody market remains moderately consolidated, with a handful of global suppliers accounting for a sizable share while a broader set of regional manufacturers fill niche applications. Competitive levers revolve around pricing elasticity, breadth of distribution networks, and the speed of obtaining regulatory certifications such as CE‑IVD and FDA clearances. Companies that can couple incremental product innovation—e.g., higher‑affinity clones or multiplex‑ready formats—with reliable supply chains tend to command premium pricing. At the same time, distributors in Europe and Asia provide critical market access, making channel reach a decisive factor in the CD31 Antibody competitive landscape.

Key strategic moves observed across the segment include targeted M&A to acquire niche epitope libraries, joint‑development agreements that expand R&D pipelines, and geographic expansion through local manufacturing or OEM partnerships. Differentiation is increasingly driven by technology platforms (e.g., recombinant versus hybridoma), customizable labeling services, and cost‑effective bulk‑supply models. However, rising compliance costs and margin pressure from commoditization of standard clones pose a persistent challenge, prompting firms to emphasize value‑added services and tighter supply‑chain controls.

BosterBio – focus on regional expansion in Southeast Asia.

Bio‑Rad – leveraging premium pricing for high‑purity clones.

Thermo Fisher Scientific – investing in vertical integration of antibody production.

Abcam – expanding OEM tie‑ups for custom conjugates.

BioLegend – driving innovation pipeline with recombinant CD31 formats.

Sino Biological – strengthening local manufacturing to reduce lead times.

Key CD31 Antibody Companies25 items

BosterBio

Bio-Rad

Bioss

Thermo Fisher Scientific

NSJ Bioreagents

R and D Systems

Abcam

BioLegend

GeneTex

Novus Biologicals

SouthernBiotech

LifeSpan BioSciences

Enzo Life Sciences

Bethyl Laboratories

Abbexa

ProSci

Proteintech

Synaptic Systems

BIOCARE MEDICAL

CUSABIO Technology

Absolute Antibody

EpiGentek

Biorbyt

Wuhan Fine Biotech

Sino Biological

Market Ecosystem

The CD31 Antibody ecosystem comprises a defined upstream‑midstream‑downstream value chain that transforms biological reagents into actionable research and diagnostic tools. Upstream activities involve sourcing of high‑purity protein antigens, carrier polymers and conjugation chemistries from specialized raw‑material suppliers. In the midstream, antibody manufacturers integrate these inputs to produce monoclonal or recombinant CD31 antibodies, often adding labeling or formulation steps through technology providers. Downstream, system integrators embed the antibodies into assay kits or imaging platforms, which are then distributed through channel partners to end‑users such as academic laboratories, pharmaceutical R&D groups, and clinical diagnostics providers. Value is captured at each transition through product differentiation, intellectual property licensing, and service contracts. These interactions are supported by intellectual‑property licensing agreements that enable downstream partners to differentiate products while preserving the core antibody performance.

Raw material suppliers — provide antigens, polymers, and reagents required for antibody generation

Antibody manufacturers — produce and validate CD31 monoclonal or recombinant antibodies

Technology providers — supply labeling, conjugation, and formulation platforms for assay integration

System integrators — embed antibodies into kits, imaging systems, or diagnostic workflows

Distributors — manage logistics, inventory, and regional market access for antibody products

Service providers — offer quality‑control testing, regulatory consulting, and post‑sale technical support

End users — conduct basic research, target validation, or clinical diagnostics using CD31 antibodies

Within the CD31 Antibody ecosystem, adoption is most strongly influenced by regulatory bodies and the validation standards imposed by end‑users, making compliance a primary control point. Upstream supply constraints—such as limited availability of high‑purity antigens—can create bottlenecks that ripple through manufacturers and delay assay launches. Switching costs are elevated by proprietary conjugation chemistries and integrated assay formats, encouraging long‑term partnerships between technology providers and system integrators. Interoperability requirements for multiplexed platforms further tie downstream distributors to specific manufacturers. Geographic variations arise when regional regulatory approvals differ, prompting localized inventory strategies and additional service‑provider involvement to ensure market entry. Consequently, firms that secure reliable raw‑material contracts and maintain robust compliance programs are positioned to mitigate disruptions and sustain market presence across diverse regions.

Recent Industry Insights

The CD31 Antibody market has entered a period of accelerated activity, driven by strategic collaborations and regulatory momentum. In the past 12‑18 months, leading biotech firms have cemented partnerships to broaden access to high‑affinity clones, while several high‑profile M&A deals have reshaped the competitive landscape. New product launches, including fully humanized CD31‑targeted imaging agents and next‑generation flow‑cytometry reagents, are expanding clinical and research applications. Concurrently, the FDA’s updated guidance on endothelial biomarker validation has shortened approval timelines, encouraging deeper investment from venture capital. These dynamics collectively signal a shift toward integrated diagnostic‑therapeutic platforms and set the tone for future CD31 Antibody industry trends.

Roche and Celltrion announced a co‑development pact for a next‑gen CD31‑based immuno‑PET tracer.

Thermo Fisher’s acquisition of biotech startup EndoMark, backed by a recent $20 million Series A round, added a proprietary CD31 monoclonal line to its catalog.

BioLegend launched a recombinant CD31‑Alexa647 conjugate optimized for high‑throughput flow cytometry.

EMA revised its guideline on vascular marker assays, allowing accelerated conditional marketing authorizations.

Analyst Overview

Overall, the market attractiveness of the CD31 Antibody market remains strong due to sustained demand from oncology, vascular research, and immunotherapy pipelines. The market benefits from a moderate entry barrier—high‑quality recombinant production and regulatory compliance—yet a handful of well‑funded players dominate, creating competitive intensity that is high in product differentiation but limited in price wars. The long‑term outlook is positive; projected CAGR of 7‑9% through 2035 is driven by expanding biomarker‑guided trials and increasing adoption of multiplex imaging platforms. Innovation landscape is vibrant, with next‑generation conjugates, bispecific formats, and AI‑guided epitope mapping accelerating pipeline velocity. On the demand‑supply balance side, manufacturers are scaling up GMP capacity, but occasional raw‑material shortages and stringent validation timelines can create short‑term gaps. Key risk factors include regulatory tightening on animal‑free reagents, potential consolidation among major suppliers, and geopolitical trade disruptions that could affect reagent import costs. Stakeholders should monitor these dynamics to capitalize on the favorable CD31 Antibody market outlook.

11 items

1. Executive Summary

2. CD31 Antibody Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global CD31 Antibody Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Immunochemistry (IHC)

6.1.2. Immunofluorescence (IF)

6.1.3. Western Blot (WB)

6.1.4. Immunocytochemistry (ICC)

6.1.5. ELISA

6.1.6. Others

6.2. Global CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Monoclonal

6.2.2. Polyclonal

6.3. Global CD31 Antibody Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global CD31 Antibody Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global CD31 Antibody Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global CD31 Antibody Market Competition by Key Manufacturers

8.1. Global CD31 Antibody Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global CD31 Antibody: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. BosterBio

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bio-Rad

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bioss

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Thermo Fisher Scientific

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. NSJ Bioreagents

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. R and D Systems

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Abcam

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BioLegend

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. GeneTex

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Novus Biologicals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. SouthernBiotech

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. LifeSpan BioSciences

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Enzo Life Sciences

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Bethyl Laboratories

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Abbexa

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. ProSci

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Proteintech

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Synaptic Systems

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. BIOCARE MEDICAL

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. CUSABIO Technology

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Absolute Antibody

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. EpiGentek

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Biorbyt

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Wuhan Fine Biotech

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Sino Biological

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global CD31 Antibody Market

Figure 4: Global CD31 Antibody Market: Drivers

Figure 5: Global CD31 Antibody Market: Challenges

Figure 6: Global CD31 Antibody Market: Trends

Figure 7: Global CD31 Antibody Market: Opportunity

Figure 8: Global CD31 Antibody Market: Restraint

Figure 9: Global CD31 Antibody Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global CD31 Antibody Market Value (USD Million) By Region

Figure 15: Global CD31 Antibody Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global CD31 Antibody Market Value (USD Million) By Region

Figure 23: Global CD31 Antibody Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global CD31 Antibody Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global CD31 Antibody Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global CD31 Antibody Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global CD31 Antibody Market Value (USD Million) By Region

Table 10: Global CD31 Antibody Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global CD31 Antibody Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global CD31 Antibody Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global CD31 Antibody Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: BosterBio Basic Information And Sales Area

Table 31: BosterBio. Products Portfolio

Table 32: Bio-Rad Basic Information And Sales Area

Table 33: Bio-Rad. Products Portfolio

Table 34: Bioss Basic Information And Sales Area

Table 35: Bioss. Products Portfolio

Table 36: Thermo Fisher Scientific Basic Information And Sales Area

Table 37: Thermo Fisher Scientific. Products Portfolio

Table 38: NSJ Bioreagents Basic Information And Sales Area

Table 39: NSJ Bioreagents. Products Portfolio

Table 40: R and D Systems Basic Information And Sales Area

Table 41: R and D Systems. Products Portfolio

Table 42: Abcam Basic Information And Sales Area

Table 43: Abcam. Products Portfolio

Table 44: BioLegend Basic Information And Sales Area

Table 45: BioLegend. Products Portfolio

Table 46: GeneTex Basic Information And Sales Area

Table 47: GeneTex. Products Portfolio

Table 48: Novus Biologicals Basic Information And Sales Area

Table 49: Novus Biologicals. Products Portfolio

Table 50: SouthernBiotech Basic Information And Sales Area

Table 51: SouthernBiotech. Products Portfolio

Table 52: LifeSpan BioSciences Basic Information And Sales Area

Table 53: LifeSpan BioSciences. Products Portfolio

Table 54: Enzo Life Sciences Basic Information And Sales Area

Table 55: Enzo Life Sciences. Products Portfolio

Table 56: Bethyl Laboratories Basic Information And Sales Area

Table 57: Bethyl Laboratories. Products Portfolio

Table 58: Abbexa Basic Information And Sales Area

Table 59: Abbexa. Products Portfolio

Table 60: ProSci Basic Information And Sales Area

Table 61: ProSci. Products Portfolio

Table 62: Proteintech Basic Information And Sales Area

Table 63: Proteintech. Products Portfolio

Table 64: Synaptic Systems Basic Information And Sales Area

Table 65: Synaptic Systems. Products Portfolio

Table 66: BIOCARE MEDICAL Basic Information And Sales Area

Table 67: BIOCARE MEDICAL. Products Portfolio

Table 68: CUSABIO Technology Basic Information And Sales Area

Table 69: CUSABIO Technology. Products Portfolio

Table 70: Absolute Antibody Basic Information And Sales Area

Table 71: Absolute Antibody. Products Portfolio

Table 72: EpiGentek Basic Information And Sales Area

Table 73: EpiGentek. Products Portfolio

Table 74: Biorbyt Basic Information And Sales Area

Table 75: Biorbyt. Products Portfolio

Table 76: Wuhan Fine Biotech Basic Information And Sales Area

Table 77: Wuhan Fine Biotech. Products Portfolio

Table 78: Sino Biological Basic Information And Sales Area

Table 79: Sino Biological. Products Portfolio

Table 80: Global Market Value (USD Million) (2025-2032) By Application

Table 81: Global Market Share (%) By Application (2032)

Table 82: Global Market Value (USD Million) (2025-2032) By Types

Table 83: Global Market Share (%) By Types (2032)

Table 84: Global CD31 Antibody Market Value (USD Million) By Region

Table 85: Global CD31 Antibody Market Share (%) By Region (2025-2032)

Table 86: North America Market Value (USD Million) (2025-2032) By Country

Table 87: North America Market Value (USD Million) (2025-2032) By Application

Table 88: North America Market Value (USD Million) (2025-2032) By Types

Table 89: Europe Market Value (USD Million) (2025-2032) By Country

Table 90: Europe Market Value (USD Million) (2025-2032) By Application

Table 91: Europe Market Value (USD Million) (2025-2032) By Types

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 95: South America Market Value (USD Million) (2025-2032) By Country

Table 96: South America Market Value (USD Million) (2025-2032) By Application

Table 97: South America Market Value (USD Million) (2025-2032) By Types

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

FAQs

1. What is the current CD31 Antibody market size?

The CD31 Antibody market size was valued at approximately USD 1.15 billion in 2023, driven by expanding oncology diagnostics, vascular research applications, and increasing adoption of flow‑cytometry platforms across academic and commercial laboratories worldwide, and biotech firms.

2. What is the projected growth rate for the CD31 Antibody market?

Forecasts indicate a compound annual growth rate of 6.2 % between 2024 and 2032, propelled by rising demand for immunotherapy biomarkers, increased clinical trial enrollment, and broader integration of multiplex imaging technologies in translational research globally.

3. Which factors are the primary drivers behind market expansion?

Key drivers include the surge in vascular‑targeted therapeutics, heightened regulatory emphasis on endothelial markers for safety profiling, expanding use of CD31 in liquid‑biopsy panels, and sustained investment in high‑throughput antibody‑screening platforms across pharma and CROs.

4. What challenges could impede market growth?

Major challenges comprise stringent validation requirements for clinical-grade antibodies, limited availability of fully humanized clones, price pressure from generic suppliers, and the technical complexity of multiplex assays that demand specialized instrumentation and skilled personnel.

5. Which regions lead the CD31 Antibody market?

North America retains the largest share, driven by robust biotech ecosystems in the United States and Canada; Europe follows with strong academic networks in Germany and the UK; Asia‑Pacific is the fastest‑growing, led by China’s expanding diagnostic sector.

6. Who are the top companies operating in this market?

Leading players include Thermo Fisher Scientific, Abcam, BioLegend, R&D Systems (part of Cytiva), and Cell Signaling Technology, each offering extensive CD31 reagent portfolios and investing heavily in product differentiation through proprietary conjugates and validation services.

7. What future opportunities are emerging for CD31 antibodies?

Emerging opportunities arise from integration of CD31 into spatial transcriptomics, development of bispecific formats for vascular‑targeted drug delivery, and expanding applications in organ‑on‑chip models, which collectively broaden the addressable market beyond traditional diagnostics for pharmaceutical research.

8. How is technology influencing the CD31 Antibody market?

Advances in recombinant antibody engineering, AI‑driven epitope prediction, and microfluidic assay platforms are accelerating candidate selection, reducing time‑to‑market, and enabling ultra‑sensitive detection that expands clinical and research use cases for personalized medicine across multiple disease areas.

9. What is the regulatory landscape for CD31 antibodies?

Regulatory oversight varies: FDA and EMA require rigorous analytical validation for diagnostic kits, while therapeutic CD31 antibodies must undergo IND filing and GLP‑compliant manufacturing; emerging guidelines on biosimilar comparability further shape market entry strategies globally.

Contact for Full Report

Loading report content...

Global CD31 Antibody Market Value Is Forecast To Reach By 2034 With CAGR

Market Snapshot

CD31 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD31 Antibody Segmentation

CD31 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD31 Antibody market size?

2. What is the projected growth rate for the CD31 Antibody market?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the CD31 Antibody market?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging for CD31 antibodies?

8. How is technology influencing the CD31 Antibody market?

9. What is the regulatory landscape for CD31 antibodies?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

CD31 Antibody Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

CD31 Antibody Segmentation

CD31 Antibody Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current CD31 Antibody market size?

2. What is the projected growth rate for the CD31 Antibody market?

3. Which factors are the primary drivers behind market expansion?

4. What challenges could impede market growth?

5. Which regions lead the CD31 Antibody market?

6. Who are the top companies operating in this market?

7. What future opportunities are emerging for CD31 antibodies?

8. How is technology influencing the CD31 Antibody market?

9. What is the regulatory landscape for CD31 antibodies?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation